Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | YAP1 | P46937 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752770 | 1.00 | BCL2 (0.64) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL7523637 | 1.00 | BCL2 (0.64) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL18025361 | 0.94 | BCL2 (0.63) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL3723164 | 0.93 | BCL2 (0.62) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL6161729 | 0.93 | BCL2 (0.64) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL3350988 | 0.93 | BCL2 (0.64) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL3500186 | 0.93 | BCL2 (0.64) | BCL2PTPN1ITGB3ITGA2BHDAC8 | |
| SCHEMBL22404737 | 0.92 | CTSS (0.64) | CTSSCTSLCTSBCTSKPPARA | |
| SCHEMBL3355326 | 0.92 | CTSS (0.64) | CTSSCTSLCTSBCTSKPPARA | |
| SCHEMBL85543 | 0.92 | CTSS (0.64) | CTSSCTSLCTSBCTSKPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638415-A1 | BIS-ESTER AND AMIDE CATIONIC LIPIDS | Sanofi Pasteur Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024133853-A1 | BIS-ESTER AND AMIDE CATIONIC LIPIDS | SANOFI (FR) | 2024-06-27 | — | — | WO | disclosed |
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | UNIVERSITY OF WARWICK (GB) | 2021-01-28 | — | — | US | disclosed |
| CN-107954937-B | Naamine derivatives, preparation method thereof and application thereof in treating plant viruses and bacterial diseases | 天津师范大学 | 2020-09-22 | — | — | CN | disclosed |
| WO-2019186174-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | UNIVERSITY OF WARWICK (GB) | 2019-10-03 | — | — | WO | disclosed |
| CN-107954937-A | Naamine analog derivatives and preparation method thereof and the application in treatment plant virus and germ disease | 天津师范大学 | 2018-04-24 | — | — | CN | disclosed |
| WO-1991010733-A1 | SYNTHETIC HELIZYME ENZYMES | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | NGLY1, MAX, VIP | BCL2 2314/4885PTPN1 2645/4885ITGB3 4170/4885 |
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | BCL2 1574/4885PTPN1 2632/4885ITGB3 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.